Description

Keytruda (pembrolizumab) is a programmed death receptor-1 (PD-1)-blocking antibody used for the treatment of various types of cancer, including:

Melanoma:

for the treatment of patients with unresectable or metastatic melanoma.
for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma after complete resection.

Non-Small Cell Lung Cancer (NSCLC):

in conjunction with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations.
in conjunction with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC.
as a monotherapy for the first-line treatment of patients with NSCLC expressing PD-L1, with no EGFR or ALK genomic tumor aberrations, and is stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic.
as a monotherapy for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%), with disease progression on or after platinum-containing chemotherapy.
for the treatment of patients with resectable (tumors ≥4 cm or node-positive) NSCLC along with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.
as a monotherapy, for adjuvant treatment after resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC.

Head and Neck Squamous Cell Cancer (HNSCC):

in conjunction with platinum and FU for the first-line treatment of patients with metastatic or unresectable, recurrent HNSCC.
as a monotherapy for the first-line treatment of patients with metastatic or unresectable, recurrent HNSCC whose tumors express PD-L1.
as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy.

Classical Hodgkin Lymphoma (cHL):

for the treatment of adult patients with relapsed or refractory cHL.
for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after two or more lines of therapy.

Primary Mediastinal Large B-Cell Lymphoma (PMBCL):

for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy.

Urothelial Cancer:

in conjunction with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer.
as a monotherapy for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy, or who have disease progression during or after platinum-containing chemotherapy or within 1 year of neoadjuvant or adjuvant therapy with platinum-containing chemotherapy.
as a monotherapy for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.

Microsatellite Instability-High or Mismatch Repair Deficient Cancer:

for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, that have progressed following prior therapy and who have no satisfactory alternative options.

Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC):

for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC).

Gastric Cancer:

in conjunction with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1).
in conjunction with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Esophageal Cancer:

for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with an epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either along with platinum- and fluoropyrimidine-based chemotherapy or as monotherapy after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10).

Cervical Cancer:

in conjunction with chemoradiotherapy, for the treatment of patients with FIGO 2014 Stage III-IVA cervical cancer.
in conjunction with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1).
as a monotherapy for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1).

Additional information

Brand	Keytruda
Generic name	Pembrolizumab injection
Form	Parenteral
Strength	100mg/4ml
Manufacturer	Merck & Co., Inc.
Documents	Either PO or prescription
Storage	2-8°C temperature
Global delivery time	10-20 days
Pay attention	Shipment should be organized from our Company with airlines only (Not FedEx, DHL, EMS, Aramex, UPS), at the specified storage condition along with one data logger.